Cost-effectiveness of nintedanib (Ofev®) for the treatment of Idiopathic Pulmonary Fibrosis
ثبت نشده
چکیده
The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Boehringer Ingelheim Ltd) economic dossier on the cost-effectiveness of nintedanib (Ofev®). The NCPE uses a decision framework to systematically assess whether a technology is costeffective. This includes clinical effectiveness and health related quality of life benefits, which the new treatment may provide and whether the cost requested by the pharmaceutical company is justified.
منابع مشابه
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
BACKGROUND International guidelines recommend nintedanib (OFEV®) as an option for the treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE The objective of this study was to assess the cost effectiveness of nintedanib versus pirfenidone, N-acetylcysteine and best supportive care (BSC) for the treatment of IPF from a UK payer's perspective. METHODS A Markov model was designed to captu...
متن کاملA Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder showcasing an interaction between genetic predisposition and environmental risks. This usually involves the coaction of a mixture of cell types associated with abnormal wound healing, leading to structural distortion and loss of gas exchange function. IPF bears fatal prognosis due to respiratory failure, re...
متن کاملEfficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
Idiopathic pulmonary fibrosis is a fatal form of progressive fibrosing interstitial pneumonia with limited treatment options. In recent years, its management has been transformed with the approval of two new antifibrotic drugs: nintedanib and pirfenidone. Nintedanib is a tyrosine kinase inhibitor that efficiently slows idiopathic pulmonary fibrosis progression and has an acceptable tolerability...
متن کاملNintedanib: a new treatment for idiopathic pulmonary fibrosis
2015 Nintedanib is an intracellular inhibitor of tyrosine kinases that has recently been approved as a treatment for idiopathic pulmonary fibrosis (IPF) by regulatory authorities in the USA and Europe. Results from the Phase II TOMORROW trial and the two replicate Phase III INPULSIS® trials have shown that nintedanib reduces disease progression in patients with IPF by reducing the annual rate o...
متن کاملComparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
BACKGROUND The treatment landscape for idiopathic pulmonary fibrosis, a devastating lung disease, is changing. To investigate the effectiveness of treatments for idiopathic pulmonary fibrosis we undertook a systematic review, network meta-analysis and indirect comparison. METHODS We searched MEDLINE, EMBASE and The Cochrane library for relevant studies. Randomised controlled trials of pirfeni...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2016